Related Experiment Video
Updated: May 17, 2026
07:45
Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer
Published on: May 18, 2020
Predicting Breast Cancer Endocrine Responsiveness Using Molecular Imaging.
Erin Currin1, Hannah M Linden, David A Mankoff
1Department of Medicine Box 354760 University of Washington 1959 N.E. Pacific St. Seattle, WA 98195 206-598-8750 (ph) ecurrin@u.washington.edu.
Current Breast Cancer Reports
|October 30, 2012
Summary
Fluorine-18-estradiol (FES) positron emission tomography (PET) can predict which estrogen receptor (ER)-positive breast cancers will respond to endocrine therapy. FES-PET also measures the effectiveness of ER-targeted treatments.
Area of Science:
- Oncology
- Nuclear Medicine
- Radiopharmacology
Background:
- Estrogen receptor (ER) expression is common in newly diagnosed breast cancers.
- Not all ER-positive tumors respond to endocrine therapy, necessitating predictive tools.
- Molecular imaging offers a functional approach to assess ER status and predict treatment response.
Purpose of the Study:
- To review the literature on 16-α[18F]-flouro-17β-estradiol (FES) positron emission tomography (PET) for predicting endocrine therapy response in breast cancer.
- To evaluate FES-PET as a functional imaging tool for ER-positive breast tumors.
- To discuss future applications of FES-PET in breast cancer management.
Main Methods:
- Review of existing literature on FES-PET in breast cancer.
- Analysis of FES-PET's role in predicting response to endocrine therapy.
- Assessment of FES-PET for measuring pharmacodynamic effects of ER-directed therapies.
Main Results:
- FES-PET has demonstrated success in imaging the estrogen receptor.
- Functional imaging with FES-PET serves as a predictive tool for endocrine therapy response.
- PET imaging of the ER can quantify the pharmacodynamic impact of endocrine treatments.
Conclusions:
- FES-PET is a valuable functional imaging modality for ER-positive breast cancer.
- FES-PET can guide patient selection for endocrine therapy.
- Further research into FES-PET applications may enhance breast cancer treatment strategies.